BMS-5

BMS-5 (LIMKi 3) is a potent LIMK inhibitor with IC50s of 7 nM and 8 nM for LIMK1 and LIMK2, respectively.

Product Specifications

CAS Number

[1338247-35-0]

Product Name Alternative

LIMKi 3

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

LIM Kinase (LIMK)

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/BMS-5.html

Concentration

10mM

Purity

99.84

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC(C)C(NC1=NC=C(C2=CC(C(F)F)=NN2C3=C(Cl)C=CC=C3Cl)S1)=O

Molecular Formula

C17H14Cl2F2N4OS

Molecular Weight

431.29

Precautions

H302, H315, H319, H335

References & Citations

[1]Ross-Macdonald P, et al. Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors. Mol Cancer Ther. 2008 Nov;7 (11) :3490-8.|[2]Petrilli A, et al. LIM Domain Kinases as Potential Therapeutic Targets for Neurofibromatosis Type 2.Oncogene. Oncogene. 2014 Jul 3;33 (27) :3571-82.|[3]Lunardi P, et al. Effects of Hippocampal LIMK Inhibition on Memory Acquisition, Consolidation, Retrieval, Reconsolidation, and Extinction. Mol Neurobiol. 2017 Jan 13.